ReviewCureus2025
Bilateral Adrenal Hemorrhage in Systemic Lupus Erythematosus and Antiphospholipid Syndrome: A Review of Mechanisms, Diagnosis, and Clinical Outcomes.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bilateral adrenal hemorrhage (BAH) is an uncommon but potentially fatal cause of adrenal insufficiency, particularly in patients with underlying hypercoagulable disorders. Autoimmune-mediated vasculitis, thrombosis, systemic lupus erythematosus (SLE), and antiphospholipid syndrome (APS) contribute to adrenal vascular compromise, yet literature on this association remains limited. We conducted a structured literature review using PubMed, focusing on articles in English published between 2000 and March 2025 that described BAH in the setting of SLE and/or APS. Search terms included "bilateral adrenal hemorrhage," "systemic lupus erythematosus," "adrenal insufficiency," "antiphospholipid syndrome," and related MeSH terms. Case reports, case series, and observational studies reporting BAH confirmed radiologically or histopathologically were included. The review identified autoimmune vasculitis, APS-related thrombosis, and hypercoagulability as major contributors to BAH. Clinical presentation is often nonspecific, with abdominal pain, hypotension, fever, and adrenal crisis as common features. Computed tomography (CT) remains the preferred initial imaging modality, while magnetic resonance imaging (MRI) offers superior sensitivity for early detection. Management requires prompt glucocorticoid and mineralocorticoid replacement, hemodynamic stabilization, and individualized anticoagulation strategies in APS-associated cases. Prognosis depends on timely diagnosis, correction of adrenal insufficiency, and control of underlying autoimmune activity. BAH in the context of SLE and APS remains a rare but life-threatening entity, and clinicians should maintain a high index of suspicion in autoimmune patients presenting with acute abdominal pain and hemodynamic instability. Early imaging, laboratory confirmation, and multidisciplinary management are essential for improving survival and long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.